Study Published in Nature Digital Medicine Shows Potential of Machine Learning and Augmented Reality-based Digital Biomarkers in Alzheimer’s Detection

Developing Digital Biomarkers for Neurological Disease Powered by Machine Learning

Altoida is developing first-of-kind, digital neurological biomarkers designed to assess cognition in clinical trials. The platform will involve a tablet-based application that uses augmented reality (AR) to replicate activities of daily living (iADLs) measuring cognitive and motoric functions via multimodal digital biomarkers.

The motoric and AR tasks in the Altoida assessment are designed to extract multimodal features, such as micro-movements, micro-errors, speed, reaction times, and navigation trajectories, which are used to train specific machine-learning models, which are known as Digital Neuro Signatures (DNS).

Altoida is developing digital biomarkers as objective indicators of cognitive performance.

Our digital biomarkers may potentially enable the measurement and monitoring of neurological disorders using digital data captured with a tablet in an administered assessment that can take a little as 10 minutes.

Altoida’s first predictive machine learning algorithm was granted FDA Breakthrough Device Designation in 2021, for use as an adjunct to other diagnostic evaluations to predict disease conversion from Mild Cognitive Impairment (MCI) to Alzheimer’s disease within 12 months. Our team is currently refining other algorithms to use the Altoida assessment for the diagnosis of MCI and MCI with likelihood of amyloid pathology, as an adjunct to other diagnostic evaluations, and plans to submit a request for marketing authorization to FDA for these or similar indications. 

Our platform is currently intended for investigational use only. The platform has not received FDA clearance or approval and is not available for commercial sale.

Why Altoida was created

Symptoms of Alzheimer’s disease appear when the condition is already too advanced for clinical management. For years, detection has been based on clinical evaluation and neuropsychological assessment batteries, such as lengthy pen-and-paper cognitive evaluations, that are associated with result variability and limit the efficiency of large-scale clinical trials.

Altoida’s mission is to develop the novel brain digital biomarkers that could potentially be useful for the assessment of cognitive and functional impairments associated with various neurodegenerative diseases.
Altoida’s objective is to enable large-scale, rapid and accurate cognitive and functional assessments enabled by multiple real-time measurements, that can potentially be applied at the earliest stages of dementia, such as mild cognitive impairment - processes at the intersection between preclinical and prodromal Alzheimer’s disease.